Compounds > 3,4-dihydroxybenzohydroxamic acid
Page last updated: 2024-10-26

3,4-dihydroxybenzohydroxamic acid and Glioblastoma with Sarcomatous Component

3,4-dihydroxybenzohydroxamic acid has been researched along with Glioblastoma with Sarcomatous Component in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Horvath, Z1
Höchtl, T1
Bauer, W1
Fritzer-Szekeres, M1
Elford, HL1
Szekeres, T1
Tihan, T1

Other Studies

1 other study available for 3,4-dihydroxybenzohydroxamic acid and Glioblastoma with Sarcomatous Component

ArticleYear
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere

2004